Overview

Lactoferrin Treatment in HIV Patients

Status:
Completed

Trial end date:
2018-01-01

Target enrollment:

Participant gender:

Summary

Our general goal is to evaluate the potential effectiveness of recombinant lactoferrin (1500mg bid) for reducing inflammation among HIV positive participants.

Phase:

Phase 2

Details

Lead Sponsor:

Jason Baker

Collaborator:

Ventria Bioscience

Treatments:

Lactoferrin